Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Methods Mol Biol ; 2214: 1-10, 2021.
Article in English | MEDLINE | ID: mdl-32944899

ABSTRACT

A couple of days after fertilization of a mouse oocyte by a sperm, two sequential cell differentiation events segregate pluripotent cells that can be identified by the presence of specific markers. Early mammalian embryos are relatively easy to recover as they are not yet implanted in the uterus matrix. Several decades of experimentation have enabled to find appropriate media to culture them, and therefore provide an excellent way to test different experimental setups such as the use of signaling inhibitors. We provide here a commonly used protocol to culture preimplantation embryos as well as a method to detect pluripotent cells in blastocysts.


Subject(s)
Blastocyst/cytology , Embryo Culture Techniques/methods , Mice/embryology , Pluripotent Stem Cells/cytology , Animals , Embryo, Mammalian/cytology , Fluorescent Antibody Technique/methods , Microscopy, Fluorescence/methods
2.
Cell Rep ; 24(11): 2799-2807.e4, 2018 09 11.
Article in English | MEDLINE | ID: mdl-30208307

ABSTRACT

Initial anatomical and physiological studies suggested that sensory information relayed from the periphery by the thalamus is serially processed in primary sensory cortical areas. It is thought to propagate from layer 4 (L4) up to L2/3 and down to L5, which constitutes the main output of the cortex. However, more recent experiments point toward the existence of a direct processing of thalamic input by L5 neurons. Therefore, the role of L2/3 neurons in the sensory processing operated by L5 neurons is now highly debated. Using cell type-specific and reversible optogenetic manipulations in the somatosensory cortex of both anesthetized and awake mice, we demonstrate that L2/3 pyramidal neurons play a major role in amplifying sensory-evoked responses in L5 neurons. The amplification effect scales with the velocity of the sensory stimulus, indicating that L2/3 pyramidal neurons implement gain control in deep-layer neurons.


Subject(s)
Pyramidal Cells/physiology , Somatosensory Cortex/cytology , Somatosensory Cortex/physiology , Animals , Cells, Cultured , Electrophysiology , Female , Mice , Optogenetics , Pyramidal Cells/metabolism , Somatosensory Cortex/metabolism
3.
Eur Neuropsychopharmacol ; 26(2): 265-279, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26727039

ABSTRACT

Depressive disorders are among the most prevalent neuropsychiatric dysfunctions worldwide, with high rates of resistance to antidepressant treatment. Genetic factors clearly contribute to the manifestation of depression as well as to the response to antidepressants. Transgenic mouse models appear as seminal tools to disentangle this complex disorder. Here, we analyzed new key aspects of the phenotype of knock-out mice for the gene encoding the serotonin 2B receptor (Htr(2B)(-/-)), including basal phenotype, ability to develop a depressive-like phenotype upon chronic isolation, and effect of chronic exposure to fluoxetine on chronically stressed Htr(2B)(-/-) mice. We find, here, that Htr(2B)(-/-) mice display an antidepressant-like phenotype, which includes reduced latency to feed in the novelty suppressed feeding test, basal increase in hippocampal BDNF levels, no change in TrkB and p75 protein levels, and an increased preference for sucrose consumption compared to wild type (Htr(2B)(+/+)) mice. Nevertheless, we show that these mice can develop depressive-like behaviors when socially isolated during four weeks. Selective serotonin reuptake inhibitors (SSRI) have been previously shown to be ineffective in non-stressed Htr(2B)(-/-) mice. We evaluated, here, the effects of the SSRI fluoxetine in chronically stressed Htr(2B)(-/-) mice and similarly no behavioral or plastic effect was induced by this antidepressant. All together, these results highlight the suitability to study resistance to SSRI antidepressants of this mouse model displaying panoply of conditions among which behavioral, neurotrophic and plastic causative factors can be analyzed.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , Depressive Disorder/genetics , Receptor, Serotonin, 5-HT2B/deficiency , Selective Serotonin Reuptake Inhibitors/therapeutic use , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cell Proliferation/drug effects , Cell Proliferation/genetics , Depressive Disorder/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior/drug effects , Feeding Behavior/drug effects , Hippocampus/drug effects , Hippocampus/physiopathology , Locomotion/drug effects , Locomotion/genetics , Male , Maze Learning/drug effects , Mice , Mice, Transgenic , Protein Binding/drug effects , Protein Binding/genetics , Reaction Time/drug effects , Receptor, Serotonin, 5-HT2B/genetics , Serotonin Plasma Membrane Transport Proteins/genetics , Serotonin Plasma Membrane Transport Proteins/metabolism , Swimming/psychology
4.
J Hypertens ; 33(11): 2310-21, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26259125

ABSTRACT

OBJECTIVE: Left-ventricular hypertrophy and interstitial fibrosis are the main pathophysiological factors of heart failure with preserved ejection fraction. Blockade of the serotonin 5-HT2B receptor (5-HT2BR) has been shown to reduce cardiac hypertrophy, oxidative stress, and extracellular cell matrix activation. In this study, we evaluated the effects of the 5-HT2BR blockade, on hemodynamic and cardiac remodeling, in spontaneously hypertensive rats (SHRs) that display a diastolic dysfunction with preserved ejection fraction. METHOD: Thirty-seven-week-old SHRs were randomized in four groups receiving either saline, the selective 5-HT2BR antagonist RS-127445 (1 mg/kg per day), a calcium channel blocker nicardipine (6 mg/kg per day), or RS-127445 + nicardipine. During the 14 weeks of treatment period, cardiac function and blood pressure were monitored by echocardiography and tail-cuff. Finally, electrocardiograms and invasive hemodynamics were obtained before blood collection. Heart was analyzed for morphology and mRNA expression. A complementary study evaluated the cardiac and vascular effects of serotonin on wild-type and mice knockout for the 5-HT2BR (Htr2B) and/or the 5-HT2AR (Htr2A). RESULTS: Despite the left ventricular 5-HT2BR overexpression, 5-HT2BR blockade by RS-127445 did not affect left ventricular hypertrophy and fibrosis in SHRs. This antagonist did not improve diastolic dysfunction, neither alone nor in combination with nicardipine, although it induced plasma brain natriuretic peptide decrease. Moreover, RS-127445 amplified subendocardial fibrosis and favored left ventricular dilatation. Finally, a subendocardial left ventricular fibrosis was induced by chronic serotonin in wild-type mice, which was increased in Htr2B animals, but prevented in Htr2A and Htr2A/2B mice, and could be explained by a contribution of the endothelial 5-HT2BRs to coronary vasodilatation. CONCLUSION: This work is the first to identify a cardioprotective function of the 5-HT2BR in an integrated model of diastolic dysfunction with preserved ejection fraction.


Subject(s)
Blood Pressure/drug effects , Hypertension/metabolism , Hypertrophy, Left Ventricular/metabolism , Serotonin Antagonists/pharmacology , Serotonin/metabolism , Ventricular Dysfunction, Left/metabolism , Animals , Blood Pressure/physiology , Echocardiography , Heart Failure/metabolism , Heart Failure/physiopathology , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Heart Ventricles/physiopathology , Hypertension/physiopathology , Hypertrophy, Left Ventricular/physiopathology , Male , Mice , Mice, Knockout , Natriuretic Peptide, Brain/metabolism , Pyrimidines/pharmacology , Rats , Rats, Inbred SHR , Receptor, Serotonin, 5-HT2A/genetics , Receptor, Serotonin, 5-HT2A/metabolism , Receptor, Serotonin, 5-HT2B/genetics , Receptor, Serotonin, 5-HT2B/metabolism , Ventricular Dysfunction, Left/physiopathology
5.
J Biol Chem ; 290(26): 16168-76, 2015 Jun 26.
Article in English | MEDLINE | ID: mdl-25931121

ABSTRACT

Voltage-dependent calcium channels (Cav) of the T-type family (Cav3.1, Cav3.2, and Cav3.3) are activated by low threshold membrane depolarization and contribute greatly to neuronal network excitability. Enhanced T-type channel activity, especially Cav3.2, contributes to disease states, including absence epilepsy. Interestingly, the intracellular loop connecting domains I and II (I-II loop) of Cav3.2 channels is implicated in the control of both surface expression and channel gating, indicating that this I-II loop plays an important regulatory role in T-type current. Here we describe that co-expression of this I-II loop or its proximal region (Δ1-Cav3.2; Ser(423)-Pro(542)) together with recombinant full-length Cav3.2 channel inhibited T-type current without affecting channel expression and membrane incorporation. Similar T-type current inhibition was obtained in NG 108-15 neuroblastoma cells that constitutively express Cav3.2 channels. Of interest, Δ1-Cav3.2 inhibited both Cav3.2 and Cav3.1 but not Cav3.3 currents. Efficacy of Δ1-Cav3.2 to inhibit native T-type channels was assessed in thalamic neurons using viral transduction. We describe that T-type current was significantly inhibited in the ventrobasal neurons that express Cav3.1, whereas in nucleus reticularis thalami neurons that express Cav3.2 and Cav3.3 channels, only the fast inactivating T-type current (Cav3.2 component) was significantly inhibited. Altogether, these data describe a new strategy to differentially inhibit Cav3 isoforms of the T-type calcium channels.


Subject(s)
Calcium Channels, T-Type/chemistry , Calcium Channels, T-Type/metabolism , Animals , Brain/metabolism , Calcium Channels, T-Type/genetics , Humans , Neurons/metabolism , Protein Structure, Secondary , Rats , Rats, Wistar
6.
Nat Neurosci ; 17(7): 923-33, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24859200

ABSTRACT

Neuronal migration disorders such as lissencephaly and subcortical band heterotopia are associated with epilepsy and intellectual disability. DCX, PAFAH1B1 and TUBA1A are mutated in these disorders; however, corresponding mouse mutants do not show heterotopic neurons in the neocortex. In contrast, spontaneously arisen HeCo mice display this phenotype, and our study revealed that misplaced apical progenitors contribute to heterotopia formation. While HeCo neurons migrated at the same speed as wild type, abnormally distributed dividing progenitors were found throughout the cortical wall from embryonic day 13. We identified Eml1, encoding a microtubule-associated protein, as the gene mutated in HeCo mice. Full-length transcripts were lacking as a result of a retrotransposon insertion in an intron. Eml1 knockdown mimicked the HeCo progenitor phenotype and reexpression rescued it. We further found EML1 to be mutated in ribbon-like heterotopia in humans. Our data link abnormal spindle orientations, ectopic progenitors and severe heterotopia in mouse and human.


Subject(s)
Choristoma/genetics , Microtubule-Associated Proteins/genetics , Microtubule-Associated Proteins/physiology , Mutation/physiology , Neural Stem Cells/physiology , Amino Acid Sequence , Animals , Bromodeoxyuridine , Cell Cycle/physiology , Cell Movement/physiology , Cerebral Cortex/cytology , Cerebral Cortex/embryology , Classical Lissencephalies and Subcortical Band Heterotopias , Doublecortin Protein , Electroporation , Humans , Immunohistochemistry , Intracranial Arteriovenous Malformations/pathology , Introns/genetics , Mice , Microscopy, Confocal , Microtubules/physiology , Mitosis/physiology , Molecular Sequence Data , Retroelements/physiology , Spindle Apparatus/physiology
7.
Mol Pharmacol ; 85(1): 127-38, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24174497

ABSTRACT

The putative role of the N-terminal region of rhodopsin-like 7 transmembrane biogenic amine receptors in agonist-induced signaling has not yet been clarified despite recent advances in 7 transmembrane receptor structural biology. Given the existence of N-terminal nonsynonymous polymorphisms (R6G;E42G) within the HTR2B gene in a drug-abusing population, we assessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharmacologic and coupling properties in transfected COS-7 cells. Modification of the 5-HT2B receptor N terminus by the R6G;E42G polymorphisms increases such agonist signaling pathways as inositol phosphate accumulation as assessed by either classic or operational models. The N-terminal R6G;E42G mutations of the 5-HT2B receptor also increase cell proliferation and slow its desensitization kinetics compared with the wild-type receptor, further supporting a role for the N terminus in transduction efficacy. Furthermore, by coexpressing a tethered wild-type 5-HT2B receptor N terminus with a 5-HT2B receptor bearing a N-terminal deletion, we were able to restore original coupling. This reversion to normal activity of a truncated 5-HT2B receptor by coexpression of the membrane-tethered wild-type 5-HT2B receptor N terminus was not observed using a membrane-tethered 5-HT2B receptor R6G;E42G N terminus. These data suggest that the N terminus exerts a negative control over basal as well as agonist-stimulated receptor activity that is lost in the R6G;E42G mutant. Our findings reveal a new and unanticipated role of the 5-HT2B receptor N terminus as a negative modulator, affecting both constitutive and agonist-stimulated activity. Moreover, our data caution against excluding the N terminus and extracellular loops in structural studies of this 7 transmembrane receptor family.


Subject(s)
Receptor, Serotonin, 5-HT2B/genetics , Amino Acid Sequence , Animals , Bioluminescence Resonance Energy Transfer Techniques , COS Cells , Cell Proliferation , Chlorocebus aethiops , GTP-Binding Protein alpha Subunits, Gq-G11/metabolism , Humans , Molecular Sequence Data , Mutation , Polymorphism, Genetic , Radioligand Assay , Serotonin 5-HT2 Receptor Agonists/pharmacology , Signal Transduction
8.
Neuropsychopharmacology ; 36(2): 423-33, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20927048

ABSTRACT

The now-banned anorectic molecule, dexfenfluramine, promotes serotonin release through a serotonin transporter-dependent mechanism, and it has been widely prescribed for the treatment of obesity. Previous studies have identified that 5-HT(2B) receptors have important roles in dexfenfluramine side effects, that is, pulmonary hypertension, plasma serotonin level regulation, and valvulopathy. We thus investigated a putative contribution of 5-HT(2B) receptors in dexfenfluramine-dependent feeding behavior in mice. Interestingly, the hypophagic response to dexfenfluramine (3-10 mg/kg) observed in wild-type mice (1-4 h) was eliminated in mice lacking 5-HT(2B) receptors (5-HT(2B)(-/-)). These findings were further validated by the lack of hypophagic response to dexfenfluramine in wild-type mice treated with RS127445, a highly selective and potent antagonist (pKi=8.22 ± 0.24). Using microdialysis, we observed that in 5-HT(2B)(-/-) awake mice, the dexfenfluramine-induced hypothalamic peak of serotonin release (1 h) was strongly reduced (fourfold) compared with wild type. Moreover, using hypothalamic synaptosomes, we established the serotonergic neuron autonomous properties of this effect: a strong serotonin release was observed upon dexfenfluramine stimulation of synaptosome preparation from wild type but not from mice lacking active 5-HT(2B) receptors. These findings strongly suggest that activation of presynaptic 5-HT(2B) receptors is a limiting step in the serotonin transporter dependent-releasing effect of dexfenfluramine, whereas other serotonin receptors act downstream with respect to feeding behavior.


Subject(s)
Appetite Depressants/pharmacology , Appetite Regulation/drug effects , Dexfenfluramine/pharmacology , Obesity/drug therapy , Receptor, Serotonin, 5-HT2B/physiology , Serotonin Receptor Agonists/pharmacology , Animals , Appetite Depressants/therapeutic use , Appetite Regulation/physiology , Dexfenfluramine/therapeutic use , Hypothalamus/drug effects , Hypothalamus/metabolism , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Obesity/genetics , Obesity/metabolism , Pyrimidines/pharmacology , Pyrimidines/therapeutic use , Receptor, Serotonin, 5-HT2B/deficiency , Receptor, Serotonin, 5-HT2B/genetics , Serotonin/metabolism , Synaptosomes/drug effects , Synaptosomes/metabolism
9.
PLoS One ; 4(11): e7952, 2009 Nov 23.
Article in English | MEDLINE | ID: mdl-19956756

ABSTRACT

The amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) reverses dopamine and serotonin transporters to produce efflux of dopamine and serotonin, respectively, in regions of the brain that have been implicated in reward. However, the role of serotonin/dopamine interactions in the behavioral effects of MDMA remains unclear. We previously showed that MDMA-induced locomotion, serotonin and dopamine release are 5-HT(2B) receptor-dependent. The aim of the present study was to determine the contribution of serotonin and 5-HT(2B) receptors to the reinforcing properties of MDMA.We show here that 5-HT(2B) (-/-) mice do not exhibit behavioral sensitization or conditioned place preference following MDMA (10 mg/kg) injections. In addition, MDMA-induced reinstatement of conditioned place preference after extinction and locomotor sensitization development are each abolished by a 5-HT(2B) receptor antagonist (RS127445) in wild type mice. Accordingly, MDMA-induced dopamine D1 receptor-dependent phosphorylation of extracellular regulated kinase in nucleus accumbens is abolished in mice lacking functional 5-HT(2B) receptors. Nevertheless, high doses (30 mg/kg) of MDMA induce dopamine-dependent but serotonin and 5-HT(2B) receptor-independent behavioral effects.These results underpin the importance of 5-HT(2B) receptors in the reinforcing properties of MDMA and illustrate the importance of dose-dependent effects of MDMA on serotonin/dopamine interactions.


Subject(s)
Gene Expression Regulation , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , Receptor, Serotonin, 5-HT2B/metabolism , Serotonin/metabolism , Animals , Behavior, Animal , Brain/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Male , Mice , Mice, Transgenic , Microscopy, Fluorescence/methods , Models, Biological , Motor Activity , Movement , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...